• 1. Enantiomeric two-fold interpenetrated 3D zinc(ii) coordination networks as a catalytic platform: significant difference between water within the cage and trace water in transesterification?
  Eunkyung Choi,Minjoo Ryu,Haeri Lee,Ok-Sang Jung Dalton Trans., 2017,46, 4595-4601
• 2. Exciton manipulation in rippled transition metal dichalcogenides?
  Chen Long,Ying Dai,Jianwei Li,Hao Jin Nanoscale, 2020,12, 21124-21130
• 3. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Benzimidazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles

2-Undecyl-1H-1,3-Benzodiazole (CAS No. 5851-51-4): An Overview of Its Properties, Applications, and Recent Research

2-Undecyl-1H-1,3-benzodiazole (CAS No. 5851-51-4) is a compound that has garnered significant attention in the fields of chemistry and pharmaceutical research due to its unique structural properties and potential applications. This compound belongs to the class of benzodiazoles, which are known for their diverse biological activities and therapeutic potential. In this article, we will delve into the chemical structure, physical properties, synthesis methods, and recent research findings related to 2-undecyl-1H-1,3-benzodiazole.

Chemical Structure and Physical Properties

2-Undecyl-1H-1,3-benzodiazole is characterized by its benzodiazole core with an undecyl substituent attached to the 2-position. The benzodiazole ring system consists of a benzene ring fused with a diazole ring, providing a rigid and planar structure. The undecyl chain, a long alkyl group, imparts hydrophobic properties to the molecule. The molecular formula of 2-undecyl-1H-1,3-benzodiazole is C₁₉H₂₄N₂, and its molecular weight is approximately 280.40 g/mol.

The physical properties of 2-undecyl-1H-1,3-benzodiazole include a melting point of around 65°C and a boiling point that is not typically reported due to its high molecular weight and stability. It is generally insoluble in water but exhibits good solubility in organic solvents such as ethanol, methanol, and dimethyl sulfoxide (DMSO). These solubility characteristics make it suitable for various chemical reactions and biological assays.

Synthesis Methods

The synthesis of 2-undecyl-1H-1,3-benzodiazole can be achieved through several routes, each with its own advantages and limitations. One common method involves the reaction of o-phthalonitrile with 1-dodecene in the presence of a strong base such as sodium hydride. This reaction proceeds via a nucleophilic addition followed by cyclization to form the benzodiazole ring. Another approach involves the condensation of o-amino benzoic acid with undecanal followed by cyclization under acidic conditions.

The choice of synthetic route often depends on factors such as yield, purity, and cost-effectiveness. Recent advancements in green chemistry have led to the development of more environmentally friendly methods for synthesizing benzodiazoles, including the use of microwave-assisted reactions and catalysts that minimize waste production.

Biological Activities and Applications

2-Undecyl-1H-1,3-benzodiazole has been studied for its potential biological activities and therapeutic applications. One area of interest is its activity as an anti-inflammatory agent. Research has shown that certain benzodiazoles can modulate inflammatory responses by inhibiting the production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). This property makes 2-undecyl-1H-1,3-benzodiazole a promising candidate for the treatment of inflammatory diseases.

In addition to anti-inflammatory activity, 2-undecyl-1H-1,3-benzodiazole has also been investigated for its potential as an antiviral agent. Studies have demonstrated that some benzodiazoles can inhibit viral replication by interfering with viral entry or assembly processes. While more research is needed to fully understand the mechanisms involved, these findings suggest that 2-undecyl-1H-1,3-benzodiazole could have applications in antiviral therapy.

Clinical Trials and Future Prospects

The potential therapeutic applications of 2-undecyl-1H-1,3-benzodiazole have led to increased interest in its clinical evaluation. Several preclinical studies have shown promising results in animal models of inflammatory diseases and viral infections. However, further clinical trials are necessary to validate these findings in human subjects.

Ongoing research aims to optimize the pharmacokinetic properties of 2-undecyl-1H-1,3-benzodiazole, such as its bioavailability and half-life, to enhance its therapeutic efficacy. Additionally, efforts are being made to develop novel delivery systems that can improve the targeting and delivery of this compound to specific tissues or cells.

Conclusion

2-Undecyl-1H-1,3-benzodiazole (CAS No. 5851-51-4) is a versatile compound with unique structural features that contribute to its diverse biological activities. Its potential applications in anti-inflammatory and antiviral therapy make it an attractive target for further research and development. As new synthetic methods and delivery systems are developed, the future prospects for this compound look promising. Continued investigation into its mechanisms of action and clinical evaluation will be crucial in realizing its full therapeutic potential.

• 1848-84-6(2-Ethylbenzimidazole)
• 36947-70-3(2-cyclohexyl-1H-1,3-benzodiazole)
• 16405-79-1(2-cyclopropyl-1H-1,3-benzodiazole)
• 5851-44-5(2-butyl-1H-1,3-benzodiazole)
• 13060-24-7(2-Octyl-1H-benzimidazole)
• 5465-29-2(2-propyl-1H-1,3-benzodiazole)
• 5851-49-0(2-Hept-1-yl-1H-benzimidazole)
• 5851-48-9(1H-Benzimidazole, 2-hexyl-)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)